Nhận xét đặc điểm các dấu ấn hóa mô miễn dịch được sử dụng tại Khoa Tế bào - Tổ chức học giai đoạn 2020

Nhận xét đặc điểm các dấu ấn hóa mô miễn dịch được sử dụng tại Khoa Tế bào - Tổ chức học giai đoạn 2020 - 2021

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Ngọc Dũng Nguyễn, Thị Mai Nguyễn, Thị Xuân Nguyễn, Vũ Thịnh Nguyễn, Hải Yến Phạm, Thị Nguyệt Anh Phí, Thái Hùng Trần

Ngôn ngữ: vie

Ký hiệu phân loại: 571.964 +Immunochemistry and immune response

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2022

Mô tả vật lý: 661-667

Bộ sưu tập: Metadata

ID: 500755

Thêm vào giỏ

Hóa mô miễn dịch (HMMD) là một công cụ rất quan trọng trong chẩn đoán xác định, chẩn đoán phân biệt, tiên lượng cũng như theo dõi điều trị ở nhiều chuyên khoa khác nhau, đặc biệt là trong chuyên khoa Huyết học. Mục tiêu: Mô tả đặc điểm các dấu ấn HMMD được sử dụng trên bệnh phẩm hạch và mô ngoài hạch. Phương pháp: 971 mẫu bệnh phẩm, mô tả cắt ngang, hồi cứu. Kết quả: U lympho (ULP) là nhóm bệnh lý phổ biến nhất (70,2% ULP không Hodgkin và 8,7% ULP Hodgkin)
CD30+/CD15+/LCA- biểu hiện đặc trưng trong ULP Hodgkin
ULP không Hodgkin tế bào B thì CD20 và CD79a dương tính 93,5% và 100%, CD5 dương tính trong 19,4%
ULP không Hodgkin tế bào T thì CD3 dương tính ở 89,8%, CD5 dương tính 100%, CD4 và CD8 dương tính với tỷ lệ tương đương (khoảng 40%), CD30 dương tính khoảng 18,4%.Immunohistochemistry is a very important instrument in diagnosis, analysis, prognosis as well as monitoring treatment in many different specialties, especially in hematology. Objectives: Describing the characteristics of some IHC markers being used on nodal or tumor biopsy samples. Methods: 971 samples, descriptive study. Results: Lymphoma was the most popular group in diagnostic (with 70.2% Non- Hodgkin lymphoma and 8.7% Hodgkin lymphoma)
CD30+/CD15+/LCA- was feature in Hodgkin lymphoma
In B-cell lymphoma, CD20 and CD79a were positive in 93.5% and 100%, and CD5 was positive in 19.4%
in T-cell lymphoma, CD3 was positive in 89.8%, CD5 was positive in 100%, CD4 and CD8 were positive in the same proportion (about 40%), CD30 was positive in about 18.4%.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR